The manager’s arrival marks a new growth phase for the company developing Artificial Intelligence solutions for cancer prevention and diagnosis.
Turin/Naples, 15 September 2026 — Health Triage announces the appointment of Guido Cannito as its new Chief Commercial Officer & Head of Market Development. With over twenty years of experience in technological innovation applied to healthcare, Cannito will lead the company’s commercial development strategies, helping to strengthen its market positioning and accelerate the adoption of Health Triage solutions by hospitals, healthcare systems and industrial partners in Italy and abroad.
Throughout his career, Cannito has built cross-functional expertise in the digital health sector, working both in Italian entrepreneurial ventures with a strong international footprint and in large multinationals engaged in the digital transformation of healthcare processes. His professional path has been shaped by one constant goal: turning technological innovation into tangible value for healthcare professionals and patients. Cannito joins at a particularly significant moment for Health Triage, which is developing Artificial Intelligence-based solutions to support cancer diagnosis and improve the efficiency of clinical pathways. In recent years the company has consolidated its positioning through research, scientific validation and national and international collaborations, laying the groundwork for market-driven growth.
“Innovation only has value when it generates a real impact on clinical practice,” says Guido Cannito. “At Health Triage I found a rare combination of scientific expertise, human talent and strategic vision. I firmly believe in the ability of Artificial Intelligence to support the work of healthcare professionals and help make care systems more effective, accessible and sustainable.”
Guido Cannito’s priorities will include strengthening relationships with key healthcare stakeholders, developing strategic partnerships and consolidating the company’s presence in European markets.
“The growth of Health Triage depends on our ability to turn years of research and development into solutions adopted by the market,” comments Davide Dettori, CEO of Health Triage. “Guido’s experience is an important asset in guiding this phase of evolution and in strengthening our dialogue with the healthcare world, institutions and industry.”
With this appointment, Health Triage confirms its intention to accelerate its growth path, strengthening its management structure and consolidating the company’s role as a leading player in innovation applied to health.
About Health Triage
Health Triage is an Italian deep tech company specialising in the development of artificial intelligence solutions for cancer prevention and diagnostics. The company is controlled by Fin Posillipo S.p.A. and counts among its shareholders Fondazione ENEA Tech e Biomedical, Vertis SGR — through the Vertis Venture 6 Digital Sud fund — and Health 1, strategic partners supporting the company’s industrial growth and internationalisation.
Health Triage currently focuses on two main areas of innovation. BreastNegative is an Artificial Intelligence-based medical device designed to automatically identify negative mammograms in breast cancer screening programmes, helping to improve the operational efficiency and sustainability of prevention pathways. Prostate V-Bio is a software technology based on an international patent and currently undergoing clinical validation. The system performs a non-invasive virtual biopsy through the analysis of biparametric magnetic resonance imaging (bpMRI).
Health Triage Press Office
Francesco Signor | M: +39 335 7864927 | E: press@healthtriage.ai | www.healthtriage.ai